Institutul De Pneumoftiziologie Marius Nasta

At Institutul De Pneumoftiziologie Marius Nasta, most of the clinical research focuses on respiratory tract diseases, with studies in asthma, chronic obstructive pulmonary disease, bronchiectasis, idiopathic pulmonary fibrosis, and pulmonary arterial hypertension. These trials are mainly designed to test new therapies, improve symptom control, and better understand how to reduce flare-ups and long-term complications.

• Research in asthma includes studies for severe and inadequately controlled disease, aiming to improve lung function and lower the risk of attacks.
• Trials in chronic obstructive pulmonary disease examine ways to reduce exacerbations and improve cardiopulmonary outcomes in people with persistent symptoms.
• Work in bronchiectasis and idiopathic pulmonary fibrosis is centered on finding better options to slow disease progression and support breathing capacity.

The site’s respiratory program also includes research on pulmonary arterial hypertension, where investigators are evaluating treatments intended to improve long-term safety, tolerability, and disease control.

Clinical trials in virus diseases at this Bucharest site include studies of COVID-19, with a focus on helping outpatients avoid hospitalization and death. The research is aimed at assessing whether new antiviral approaches can offer added benefit alongside supportive care.

• COVID-19 studies are evaluating treatment effectiveness in high-risk patients managed outside the hospital.
• The main goal is to identify therapies that can reduce severe outcomes and improve recovery in infected participants.

This area reflects the hospital’s interest in practical infectious-disease research that can support earlier and more effective care.

The site also conducts research in nutritional and metabolic diseases, including weight management studies. These trials are designed to test whether new treatment approaches can support healthier body weight when combined with lifestyle changes.

• Weight management research is focused on helping participants achieve meaningful reductions in body weight.
• The studies aim to evaluate the effectiveness of new therapies as part of a broader plan that includes diet and physical activity.

This work broadens the research portfolio beyond lung disease and addresses an important factor linked to overall health.

In the area of cardiovascular diseases, the main focus is on pulmonary arterial hypertension, a serious condition that affects blood flow in the lungs and can place strain on the heart. Trials at Institutul De Pneumoftiziologie Marius Nasta are evaluating new treatment options intended to improve symptoms, delay worsening, and support longer-term disease management.

• Pulmonary arterial hypertension studies are testing therapies that may help reduce clinical worsening and improve patient outcomes.
• Research also examines safety and tolerability over time, which is important in a chronic condition requiring ongoing care.

This cardiovascular-focused work is closely connected to the site’s broader expertise in complex lung and heart-lung disorders.